|
EP1969010A1
|
|
Anti-inflammatory dab
|
|
AU2002951108A0
|
|
Receptor specific ligands
|
|
US6451983B2
|
|
Tumor necrosis factor antibodies
|
|
US6375928B1
|
|
Neutrophil stimulating peptides
|
|
AUPQ591200A0
|
|
Novel peptides
|
|
AUPQ223899A0
|
|
Bioimplant formulation iv
|
|
AU4889099A
|
|
Bioimplant formulation
|
|
CN1310623A
|
|
Bioimplant formulation
|
|
AUPP934399A0
|
|
Process
|
|
AUPP900899A0
|
|
Novel peptides
|
|
AU1843899A
|
|
Novel formulation for peptide release
|
|
AUPP473098A0
|
|
Bioimplant formulation I
|
|
AUPP473198A0
|
|
Bioimplant formulation II
|
|
US6337318B1
|
|
Sustained GnRH peptide-release formulation
|
|
AU2498897A
|
|
Methods of treating immunopathologies using polyunsaturated fatty acids
|
|
EP0869941A1
|
|
Modified polyunsaturated fatty acids
|
|
EP0666753A4
|
|
Use of peptides FOR THE TREATMENT OF THE COMPLICATIONS AND PATHOLOGY OF DIABETES
|
